VRDN Viridian Therapeutics, Inc.
USHealthcareAs of 2026-07-09 11:30
Why VRDN matters now
Viridian Therapeutics, Inc. (VRDN) is a US stock in Healthcare. The latest InvestLog snapshot shows $20.08 with +1.11% on the session and $1.81B in market capitalization; recent performance reads 1-month +4.13% and YTD -46.56%.
The latest financial table shown here is Q1 2026, with revenue of $141.0K, net income of $-104.9M, and EPS of $-1.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -20.3%.
The latest indexable market news headline is "VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $34.00; recent insider activity includes Fairmount Funds Management LLC filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.67
P/S
21.10
EV/EBITDA
-3.92
DCF Value
$-7.63
FCF Yield
-20.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-543.9%
Net Margin
-508.5%
ROE
-60.7%
ROA
-45.7%
ROIC
-52.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $141.0K | $-104.9M | $-1.03 |
| Q4 2025 | $132.0K | $-120.4M | $-1.11 |
| FY 2025 | $70.8M | $-342.6M | $-3.32 |
| Q3 2025 | $70.6M | $-34.6M | $-0.34 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$36.86
Target (Median)
$34.00
Target Range
$26.00 - $50.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.90
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.